Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.19.1
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income
Total New Residential Stockholders’ Equity
Noncontrolling Interests in Equity of Consolidated Subsidiaries
Equity, beginning balance (in shares) at Dec. 31, 2017   307,361,309          
Equity, beginning balance at Dec. 31, 2017 $ 4,796,162 $ 3,074 $ 3,763,188 $ 559,476 $ 364,467 $ 4,690,205 $ 105,957
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Dividends declared (168,068)     (168,068)   (168,068)  
Capital contributions 0            
Capital distributions (18,317)           (18,317)
Issuance of common stock (in shares)   28,750,000          
Issuance of common stock 482,253 $ 288 481,965     482,253  
Director share grants (in shares)   24,082          
Director share grants 420   420     420  
Comprehensive income (loss)              
Net income (loss) 614,364     604,253   604,253 10,111
Net unrealized gain (loss) on securities 18,976       18,976 18,976  
Reclassification of net realized (gain) loss on securities into earnings 35,897       35,897 35,897  
Total comprehensive income (loss) 669,237         659,126 10,111
Equity, ending balance (in shares) at Mar. 31, 2018   336,135,391          
Equity, ending balance at Mar. 31, 2018 5,761,687 $ 3,362 4,245,573 995,661 419,340 5,663,936 97,751
Equity, beginning balance (in shares) at Dec. 31, 2018   369,104,429          
Equity, beginning balance at Dec. 31, 2018 6,088,295 $ 3,692 4,746,242 830,713 417,023 5,997,670 90,625
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Dividends declared (207,715)     (207,715)   (207,715)  
Capital contributions 0            
Capital distributions (11,015)           (11,015)
Issuance of common stock (in shares)   46,000,000          
Issuance of common stock $ 751,659 $ 460 751,199     751,659  
Options exercise (in shares) 1,641,222 297,096          
Option exercise $ 0 $ 3 (3)        
Other dilution 0            
Purchase of noncontrolling interests in the Buyer 0            
Director share grants (in shares)   28,152          
Director share grants 400   400     400  
Comprehensive income (loss)              
Net income (loss) 155,912     145,594   145,594 10,318
Net unrealized gain (loss) on securities 192,353       192,353 192,353  
Reclassification of net realized (gain) loss on securities into earnings (57,680)       (57,680) (57,680)  
Total comprehensive income (loss) 290,585         280,267 10,318
Equity, ending balance (in shares) at Mar. 31, 2019   415,429,677          
Equity, ending balance at Mar. 31, 2019 $ 6,912,209 $ 4,155 $ 5,497,838 $ 768,592 $ 551,696 $ 6,822,281 $ 89,928